Patents by Inventor Kaiwei Liang

Kaiwei Liang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • SEALING ASSEMBLY AND ROBOT
    Publication number: 20240175494
    Abstract: A sealing assembly which has a housing adapted to be arranged on and cover an end of a first component of a robot. The sealing assembly includes a circumferential coupling section; a flange adapted to be arranged on and cover an end of a second component of the robot that is coaxially rotatable relative to the first component; and an elastic sealing ring. The elastic sealing ring includes a coupling portion coupled to the circumferential coupling section; and a sealing portion arranged between the housing and the flange with an interference fit.
    Type: Application
    Filed: May 3, 2020
    Publication date: May 30, 2024
    Inventors: Linjian Liang, Xiaodong Cao, Kaiwei Chen, Jiajie Sha, Yun Ha
  • Small molecules for disrupting the super elongation complex and inhibiting transcription elongation for cancer therapy
    Patent number: 11453640
    Abstract: Disclosed are compounds which may be utilized to inhibit transcription by RNA Polymerase II (Pol II), and in particular to disrupt the Super Elongation Complex (SEC). The compounds may be utilized in pharmaceutical compositions and methods for treating diseases and disorders associated with the biological activity of SEC, and in particular, diseases and disorders that are associated with high levels of expression of genes whose expression is SEC-dependent and that promote, support, or otherwise are required for the disease or disorder such as cancers.
    Type: Grant
    Filed: March 21, 2019
    Date of Patent: September 27, 2022
    Assignee: Northwestern University
    Inventors: Ali Shilatifard, Kaiwei Liang, Edwin R. Smith, Gary E. Schiltz, Rama K. Mishra, Kristen Stoltz
  • Therapeutic targeting of interleukin-1 receptor-associated kinase 4 (IRAK4) in cancers characterized by rearrangements in the mixed lineage leukemia gene (MLL-r)
    Patent number: 10640502
    Abstract: Disclosed are methods for treating cancers associated with rearrangements in the mixed lineage leukemia gene (MLL-r), including MLL-r leukemia. The methods typically include administering a therapeutic amount of one or more therapeutic agents that inhibit the biological activity of one or more members of the interleukin-1 signaling pathway such inhibitors of interleukin-1 receptor-associated kinase 4 (IRAK4).
    Type: Grant
    Filed: July 9, 2018
    Date of Patent: May 5, 2020
    Assignee: Northwestern University
    Inventors: Ali Shilatifard, Kaiwei Liang, Edwin Richard Smith, Gary E. Schiltz
  • THERAPEUTIC TARGETING OF INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASE 4 (IRAK4) IN CANCERS CHARACTERIZED BY REARRANGEMENTS IN THE MIXED LINEAGE LEUKEMIA GENE (MLL-r)
    Publication number: 20180319795
    Abstract: Disclosed are methods for treating cancers associated with rearrangements in the mixed lineage leukemia gene (MLL-r), including MLL-r leukemia. The methods typically include administering a therapeutic amount of one or more therapeutic agents that inhibit the biological activity of one or more members of the interleukin-1 signaling pathway such inhibitors of interleukin-1 receptor-associated kinase 4 (IRAK4).
    Type: Application
    Filed: July 9, 2018
    Publication date: November 8, 2018
    Applicant: Northwestern University
    Inventors: Ali Shilatifard, Kaiwei Liang, Edwin Richard Smith
  • Therapeutic targeting of the interleukin 1 receptor-associated kinase 4 (IRAK4) in leukemias characterized by rearrangements in the mixed lineage leukemia gene (MLL-r)
    Patent number: 10059708
    Abstract: Disclosed are methods for treating cancers associated with rearrangements in the mixed lineage leukemia gene (MLL-r), including MLL-r leukemia. The methods typically include administering a therapeutic amount of one or more therapeutic agents that inhibit the biological activity of one or more members of the interleukin-1 signaling pathway such inhibitors of interleukin-1 receptor-associated kinase 4 (IRAK4).
    Type: Grant
    Filed: April 26, 2017
    Date of Patent: August 28, 2018
    Assignee: Northwestern University
    Inventors: Ali Shilatifard, Kaiwei Liang, Edwin Richard Smith
  • THERAPEUTIC TARGETING OF INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASE 4 (IRAK4) IN CANCERS CHARACTERIZED BY REARRANGEMENTS IN THE MIXED LINEAGE LEUKEMIA GENE (MLL-r)
    Publication number: 20170305901
    Abstract: Disclosed are methods for treating cancers associated with rearrangements in the mixed lineage leukemia gene (MLL-r), including MLL-r leukemia. The methods typically include administering a therapeutic amount of one or more therapeutic agents that inhibit the biological activity of one or more members of the interleukin-1 signaling pathway such inhibitors of interleukin-1 receptor-associated kinase 4 (IRAK4).
    Type: Application
    Filed: April 26, 2017
    Publication date: October 26, 2017
    Applicant: Northwestern University
    Inventors: Ali Shilatifard, Kaiwei Liang, Edwin Richard Smith